With the continuous increase in the number of patients with obesity, type 2 diabetes (T2DM), and metabolic diseases both globally and in China, scientific and effective prevention and control strategies, healthy lifestyles, clinical treatments, and the development of new and efficient therapeutic drugs have become an urgent priority in the medical field. Against this backdrop, China's medical innovation system has been continuously improving, and the field of diabetes prevention and treatment has witnessed technological breakthroughs and paradigm shifts. Particularly, the research breakthroughs in new hypoglycemic mechanisms such as ultra-long-acting GLP-1 receptor agonists are driving the treatment of related diseases towards precision and individualization, providing more clinically valuable solutions for patient management. The academic symposium "Yitantongjiu - Exploring the Latest Advances in GLP-1 Drugs", hosted by the Chengdu High-tech Medical Association, was held on August 1, 2025. Experts and scholars in the field of endocrine and metabolic diseases gathered to discuss the local innovation achievements in drugs for endocrine and metabolic treatments, evaluating the application value of innovative drugs from both clinical practice and academic research perspectives, and contributing wisdom and strength to the high-quality development of China's biomedicine and clinical diagnosis and treatment innovation.